180 related articles for article (PubMed ID: 36859697)
1. A Cross-Sectional Study of Tampering in Xtampza ER, an Abuse-Deterrent Formulation of an Extended-Release Opioid, in a Treatment Center Population.
Jewell J; Black J; Ellis M; Olsen H; Iwanicki J; Dart R
Clin Drug Investig; 2023 Mar; 43(3):197-203. PubMed ID: 36859697
[TBL] [Abstract][Full Text] [Related]
2. Postmarketing Analysis of Misuse, Abuse, and Diversion of Xtampza ER.
Geoffrey Severtson S; Kreider SED; Amioka EC; Margolin ZR; Iwanicki JL; Dart RC
Pain Med; 2020 Dec; 21(12):3660-3668. PubMed ID: 33094329
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the durability of pain relief throughout a 12 hour dosing interval of a novel, extended-release, abuse-deterrent formulation of oxycodone.
Nalamachu S; Kopecky EA; Taylor R; Vaughn B; O'Connor M
Curr Med Res Opin; 2016 Jul; 32(7):1311-7. PubMed ID: 27025986
[TBL] [Abstract][Full Text] [Related]
4. Differences in severity of poison centers exposures involving XTAMPZA
Severtson SG; Haanschoten EE; Iwanicki J; Dart RC
Pain Manag; 2023 Sep; 13(9):519-527. PubMed ID: 37850331
[No Abstract] [Full Text] [Related]
5. Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation.
Cassidy TA; DasMahapatra P; Black RA; Wieman MS; Butler SF
Pain Med; 2014 Mar; 15(3):440-51. PubMed ID: 24330279
[TBL] [Abstract][Full Text] [Related]
6. Use of prescription opioids with abuse-deterrent technology to address opioid abuse.
Michna E; Kirson NY; Shei A; Birnbaum HG; Ben-Joseph R
Curr Med Res Opin; 2014 Aug; 30(8):1589-98. PubMed ID: 24738694
[TBL] [Abstract][Full Text] [Related]
7. A tale of 2 ADFs: differences in the effectiveness of abuse-deterrent formulations of oxymorphone and oxycodone extended-release drugs.
Cicero TJ; Ellis MS; Kasper ZA
Pain; 2016 Jun; 157(6):1232-1238. PubMed ID: 27186712
[TBL] [Abstract][Full Text] [Related]
8. Effect of physical manipulation on the oral pharmacokinetic profile of Xtampza
Gudin J
J Opioid Manag; 2020; 16(2):127-139. PubMed ID: 32329888
[TBL] [Abstract][Full Text] [Related]
9. Changes in drug use patterns reported on the web after the introduction of ADF OxyContin: findings from the Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS) System Web Monitoring Program.
Vosburg SK; Haynes C; Besharat A; Green JL
Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1044-1052. PubMed ID: 28653782
[TBL] [Abstract][Full Text] [Related]
10. Abuse-deterrent properties of REMOXY® ER, a high-viscosity extended-release oxycodone formulation.
Kucera SA; Zamloot MS; Crowley MM; Burns LH; Friedmann N; Barbier R
J Opioid Manag; 2018; 14(6):429-436. PubMed ID: 30629279
[TBL] [Abstract][Full Text] [Related]
11. The Impact of Food on Bioavailability of Oxycodone Myristate: A Case Report.
Nguyen TP; Hagiwara Y; Pies C; Lockman K
J Palliat Care; 2021 Jul; 36(3):148-150. PubMed ID: 33327849
[TBL] [Abstract][Full Text] [Related]
12. Mitigation of IV Abuse Through the Use of Abuse-Deterrent Opioid Formulations: An Overview of Current Technologies.
Rauck RL
Pain Pract; 2019 Apr; 19(4):443-454. PubMed ID: 30597739
[TBL] [Abstract][Full Text] [Related]
13. Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties.
Gudin J; Levy-Cooperman N; Kopecky EA; Fleming AB
Pain Med; 2015 Nov; 16(11):2142-51. PubMed ID: 26108255
[TBL] [Abstract][Full Text] [Related]
14. Impact of Abuse Deterrent Formulations of Opioids in Patients With Chronic Pain in the United States: A Cost-Effectiveness Model.
Kumar VM; Agboola F; Synnott PG; Segel C; Webb M; Ollendorf DA; Banken R; Chapman RH
Value Health; 2019 Apr; 22(4):416-422. PubMed ID: 30975392
[TBL] [Abstract][Full Text] [Related]
15. Abuse-deterrent extended-release oxycodone and risk of opioid-related harm.
Paljarvi T; Strang J; Quinn PD; Luciano S; Fazel S
Addiction; 2021 Sep; 116(9):2409-2415. PubMed ID: 33394528
[TBL] [Abstract][Full Text] [Related]
16. A nasal abuse potential randomized clinical trial of REMOXY® ER, a high-viscosity extended-release oxycodone formulation.
Friedmann N; Marsman MR; de Kater AW; Burns LH; Webster LR
J Opioid Manag; 2018; 14(6):437-443. PubMed ID: 30629280
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of an Extended-Release, Abuse-Deterrent, Microsphere-in-Capsule Analgesic for the Management of Patients with Chronic Pain With Dysphagia (CPD).
Fleming AB; Carlson DR; Varanasi RK; Grima M; Mayock SP; Saim S; Kopecky EA
Pain Pract; 2016 Mar; 16(3):334-44. PubMed ID: 25639548
[TBL] [Abstract][Full Text] [Related]
18. Oxycodone extended release capsules for the treatment of chronic pain.
Mercadante S
Expert Rev Neurother; 2017 May; 17(5):427-431. PubMed ID: 28277802
[TBL] [Abstract][Full Text] [Related]
19. Oral Human Abuse Potential of Oxycodone DETERx
Kopecky EA; Fleming AB; Levy-Cooperman N; O'Connor M; M Sellers E
J Clin Pharmacol; 2017 Apr; 57(4):500-512. PubMed ID: 27669664
[TBL] [Abstract][Full Text] [Related]
20. Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US.
Rossiter LF; Kirson NY; Shei A; White AG; Birnbaum HG; Ben-Joseph R; Michna E
J Med Econ; 2014 Apr; 17(4):279-87. PubMed ID: 24559196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
